Systemic Review: Is an Intradiscal Injection of Platelet-Rich Plasma for Lumbar Disc Degeneration Effective?

Takashi Hirase, Robert A Jack Ii, Kyle R Sochacki, Joshua D Harris, Bradley K Weiner, Takashi Hirase, Robert A Jack Ii, Kyle R Sochacki, Joshua D Harris, Bradley K Weiner

Abstract

Current studies evaluating the outcomes of intradiscal platelet-rich plasma (PRP) injections in degenerative disc disease (DDD) are limited. The purpose of this review was to determine if an intradiscal injection of PRP for degenerative discs results in a statistically significant improvement in clinical outcomes. A systematic review was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Level I-IV investigations of intradiscal PRP injections in DDD were sought in multiple databases. The Modified Coleman Methodology Score (MCMS) was used to analyze the methodological quality of the study. Only the outcome measurements used by more than 50% of the studies were included in the data analysis. The study heterogeneity and nature of evidence (mostly retrospective, non-comparative) precluded meta-analysis. Pre and post-injection pain visual analog scales (VAS) were compared using two sample Z-tests. Five articles (90 subjects, mean age 43.6 ± 7.7 years, mean follow-up 8.0 ± 3.6 months) were analyzed. Four articles were level IV evidence and one article was level II. Mean MCMS was 56.0 ± 10.3. There were 43 males and 37 females (10 unidentified). Pain VAS significantly improved following lumbar intradiscal PRP injection (69.7 mm to 43.3 mm; p<0.01). Two patients (2.2%) experienced lower extremity paresthesia after treatment. One patient (1.1%) underwent re-injection. No other complications were reported. In conclusion, intradiscal injection of PRP for degenerative discs resulted in statistically significant improvement in VAS with low re-injection and complication rates in this systematic review. It is unclear whether the improvements were clinically significant given the available evidence. The low level of evidence available (level IV) does not allow for valid conclusions regarding efficacy; however, the positive results suggest that further higher-quality studies might be of value.

Keywords: degenerative disc disease; intradiscal injection; platelet-rich plasma.

Conflict of interest statement

The authors have declared financial relationships, which are detailed in the next section.

Copyright © 2020, Hirase et al.

Figures

Figure 1. Flow diagram summarizing the literature…
Figure 1. Flow diagram summarizing the literature search, screening, and review
PRP (Platelet-Rich Plasma)

References

    1. Epidemiological features of chronic low-back pain. Andersson GB. Lancet. 1999;354:581–585.
    1. Disability resulting from occupational low back pain. Part I: What do we know about primary prevention? A review of the scientific evidence on prevention before disability begins. Frank JW, Brooker AS, DeMaio SE, et al. Spine. 1996;21:2908–2917.
    1. Low back pain. A primary care challenge. Deyo RA, Phillips WR. Spine. 1996;21:2826–2832.
    1. The prevalence and clinical features of internal disc disruption in patients with chronic low back pain. Schwarzer AC, Aprill CN, Derby R, Fortin J, Kine G, Bogduk N. Spine. 1995;20:1878–1883.
    1. Outcome of low back pain in general practice: a prospective study. Croft PR, Macfarlane GJ, Papageorgiou AC, Thomas E, Silman AJ. BMJ. 1998;316:1356.
    1. Acute low back pain: systematic review of its prognosis. Pengel LH, Herbert RD, Maher CG, Refshauge KM. BMJ. 2003;327:323.
    1. Conservative treatment of sciatica: a systematic review. Vroomen PC, de Krom MC, Slofstra PD, Knottnerus JA. J Spinal Disord. 2000;13:463–469.
    1. Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. Luijsterburg PA, Verhagen AP, Ostelo RW, van Os TA, Peul WC, Koes BW. Eur Spine J. 2007;16:881–899.
    1. Patient outcomes after lumbar spinal fusions. Turner JA, Ersek M, Herron L, Haselkorn J, Kent D, Ciol MA, Deyo RA. JAMA. 1992;268:907–911.
    1. Morbidity and mortality in association with operations on the lumbar spine. The influence of age, diagnosis and procedure. Deyo RA, Cherkin DC, Loeser JD, Bigos SJ, Ciol MA. . J Bone Joint Surg Am. 1992;74:536–543.
    1. Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. Deyo RA, Mirza SK, Martin BI, Kreuter W, Goodman DC, Jarvik JG. JAMA. 2010;303:1259–1265.
    1. Spinal fusion in the United States: analysis of trends from 1998 to 2008. Rajaee SS, Bae HW, Kanim LE, Delamarter RB. Spine. 2012;37:67–76.
    1. The assessment of complications after spine surgery: time for a paradigm shift? Mannion AF, Fekete TF, O'Riordan D, et al. Spine. 2013;13:615–624.
    1. What is the clinical evidence on regenerative medicine in intervertebral disc degeneration? Basso M, Caagnaro L, Zanirato A, Divano S, Formica C, Formica M, Felli L. Musculoskelet Surg. 2017;101:93–104.
    1. Platelet-rich plasma: from basic science to clinical applications. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Am J Sports Med. 2009;37:2259–2272.
    1. Platelet-rich plasma enhances the initial mobilization of circulation-derived cells for tendon healing. Kajikawa Y, Morihara T, Sakamoto H, et al. J Cell Physiol. 2008;215:837–845.
    1. Use of growth factors to improve muscle healing after strain injury. Kasemkijwattana C, Menetrey J, Bosch P, et al. Clin Orthop Relat Res. 2000;370:272–285.
    1. Histology and pathology of the human intervertebral disc. Roberts S, Evans H, Trivedi J, Menage J. J Bone Joint Surg Am. 2006;88:10–14.
    1. Platelet-rich plasma application in chondrogenesis. Kabiri A, Esfandiari E, Esmaeili A, Hashemibeni B, Pourazar A, Mardani M. Adv Biomed Res. 2014;3:138.
    1. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Van Buul GM, Koevoet WL, Kops N, et al. Am J Sports Med. 2011;39:2362–2370.
    1. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kappa B inhibition via HGF. Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, Desiderio MA. J Cell Physiol. 2010;225:757–766.
    1. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. PLoS Med. 2009;6:1000097.
    1. The 2011 Oxford CEBM evidence levels of evidence (introductory document) Howick J, Chalmers I, Glasziou P, et al. Oxford Centre for Evidence-Based Medicine. 2011
    1. How to write a systematic review. Harris JD, Quatman CE, Manring MM, Siston RA, Flanigan DC. Am J Sports Med. 2014;42:2761–2768.
    1. Studies of surgical outcome after patellar tendinopathy: clinical significance of methodological deficiencies and guidelines for future studies. Coleman B, Khan K, Maffulli N, Cook J, Wark JD. Scand J Med Sci Sports. 2000;10:2–11.
    1. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M. Am Fam Physician. 2004;69:549–557.
    1. GRADE Working Group. [Apr;2020 ];GRADE Working Group. (2007. 2000
    1. Best evidence synthesis: an intelligent alternative to meta-analysis. Slavin RE. J Clin Epidemiol. 1995;48:9–18.
    1. Minimum clinically important difference and substantial clinical benefit in pain, functional and quality of life scales in failed back surgery syndrome patients. Park KB, Shin JS, Lee J, et al. Spine. 2017;42:474–481.
    1. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Tuback F, Pham T, Skomsvoll JF, et al. Arthritis Rheum. 2006;55:960–963.
    1. Lumbar intradiskal platelet-rich plasma (PRP) injections: a prospective, double-blind, randomized controlled study. Tuakli-Wosornu YA, Terry A, Boachie-Adjei K, et al. Am J Phys Med Rehabil. 2016;8:1–10.
    1. Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease. Comella K, Silbert R, Parlo M. J Transl Med. 2017;15:12.
    1. Intradiscal injection of autologous platelet-rich plasma releasate to treat discogenic low back pain: a preliminary clinical trial. Akeda K, Ohishi K, Masuda K, et al. Asian Spine J. 2017;11:380–389.
    1. Intradiscal platelet-rich plasma injection for chronic discogenic low back pain: preliminary results from a prospective trial. Levi D, Horn S, Tyszko S, Levin J, Hecht-Leavitt C, Walko E. Pain Medicine. 2016;17:1010–1022.
    1. Efficacy of platelet rich plasma via lumbar epidural route in chronic prolapsed intervertebral disc patients-a pilot study. Bhatia R, Chopra G. J Clin Diag Res. 2016;10:5–7.
    1. Understanding the relevance of measured change through studies of responsiveness. Beaton DE. Spine. 2000;25:3192–3199.
    1. A guide to interpreting epidemiologic studies on the etiology of back pain. Bombardier C, Kerr MS, Shannon HS, Frank JW. Spine. 1994;19:2047–2056.
    1. The significance of treatment effects: the clinical perspective. Deyo RA, Patrick DL. Med Care. 1995;33:286–291.
    1. Reproducibility and responsiveness of health status measures statistics and strategies for evaluation. Deyo RA, Diehr P, Patrick DL. Control Clin Trials. 1991;12:142–158.
    1. Responsiveness in quality-of-life assessment: nomenclature, determinants, and clinical applications. Epstein RS. Med Care. 2000;38:91–94.
    1. Measurement of health status. Ascertaining the minimal clinically important difference. Jaeschke R, Singer J, Guyatt GH. Control Clin Trials. 1989;10:407–415.
    1. Defining substantial clinical benefit following lumbar spine arthrodesis. Glassman SD, Copay AG, Berven SH, Polly DW, Subach BR, Carreon LY. J Bone Joint Surg Am. 2008;90:1839–1847.
    1. Minimally clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease. Tashjian RZ, Deloach J, Porucznik CA, Powell AP. J Shoulder Elbow Surg. 2009;18:927–932.
    1. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. Dragoo JL, Braun HJ, Durham JL, Ridley BA, Odegaard JI, Luong R, Arnoczky SP. Am J Sports Med. 2012;40:1274–1281.
    1. The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy. Braun HJ, Kim HJ, Chu CR, Dragoo JL. Am J Sports Med. 2014;42:1204–1210.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi